Monoclonal antibodies in the treatment of advanced colorectal cancer
- 31 December 2007
- journal article
- review article
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 33, S24-S34
- https://doi.org/10.1016/j.ejso.2007.09.025
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Neuropilin-1 Suppresses Tumorigenic Properties in a Human Pancreatic Adenocarcinoma Cell Line Lacking Neuropilin-1 CoreceptorsCancer Research, 2005
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005
- Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor ReceptorJournal of Clinical Oncology, 2004
- Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor ReceptorJournal of Clinical Oncology, 2004
- Molecular regulation of vessel maturationNature Medicine, 2003
- Therapies directed at vascular endothelial growth factorExpert Opinion on Investigational Drugs, 2002
- VEGF and the quest for tumour angiogenesis factorsNature Reviews Cancer, 2002
- Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transductionNature, 1995
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993
- Epidermal growth factor receptor expression in colorectal cancerBritish Journal of Surgery, 1990